RE:RE:RE:RE:RE:Antibody-Drug Conjugate (ADC) developments Following reports of an ex-AstraZeneca executive being detained in China, the company acknowledged that its current president in the country, Leon Wang, "is cooperating with an ongoing investigation."
The development surrounding Wang comes quickly on the heels of a report that BeiGene executive Eva Yin had been detained by anti-smuggling authorities in Shenzhen. Before joining BeiGene, Yin spent 15 years with AstraZeneca, including as head of its oncology business in China for part of that time.
Prior to that, Chinese authorities in January 2022 accused some AZ staffers of running an insurance swindle, tampering with genetic testing results to put ineligible patients on the company’s EGFR inhibitor Tagrisso. The case started in Shenzhen.
AZ’s China president and executive vice president of international markets, Leon Wang, is related to an insurance fraud case that first emerged about three years ago.
Before joining AZ, Wang served in several roles at Roche, according to the biography.
https://www.fiercepharma.com/pharma/astrazenecas-china-president-faces-ongoing-investigation-authorities-country